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Occult hepatitis B virus (OBI) in HIV-infected groups is still debated, as well as the associated risk-factors and clinical significance.
In this paper, we examined a total of 405 HBsAg-negative/HIV-infected patients enrolled from January 2007 to December 2009.
Overall, the prevalence of OBI was 5.9% (95% confidence interval (CI
95%): 3.8–8.7%); it was more frequently associated with “anti-
HBc alone” serological marker (11.3%; adjusted odds ratio = 3.7, CI
95%: 1.4–9.8), although it was also detected in the absence of any
HBV serological marker (4.9%; CI
95%: 2.3–9.1%). A low prevalence of anti-HCV-positive patients with OBI was found (3.1%; CI95%:
0.6–8.7%). HIV RNA plasma levels or other immunological/clinical characteristics were not significantly associated with OBI. All
but one occult HBV infections were sustained by genotype D viral strains. OBI is relatively frequent in HIV-infected patients,
although it does not seem to exert a relevant clinical impact. Viral genotypes in occult HBV infections reflect those circulating in
the Mediterranean area.
1. Introduction
The term “occult” hepatitis B infection (OBI) is defined by
the presence of HBV DNA in plasma and/or liver tissue
of subjects who lack detectable hepatitis B surface antigen
(HBsAg).
Occult HBV infections are more frequently detected in
individuals with antibodies to hepatitis B core antigen (anti-
HBc) [1], often as unique marker of HBV infection [2, 3].
Nevertheless, recent estimates suggest that up to 20% of
individuals with occult HBV could be negative even for anti-
HBc antibodies or any other serological indicator of exposure
toHBV [4], indicating that diagnosis of occult HBV infection
is still an unresolved issue [5].
Theprevalence of occultHBV inHIV-positive individuals
remains controversial, varying between 0% and 90% [6–10],
and the clinical significance is still unclear.
Nevertheless, occult HBV infection has important impli-
cations in HIV coinfected groups, being associated with
faster rate of liver disease progression toward cirrhosis and
hepatocellular carcinoma [11].
Although the impact of occult HBV infection has been
investigated in different countries [3, 7, 9, 12–14] and clinical
settings [15], no data are available on the prevalence of OBI
among HIV-positive individuals from our geographic area.
A cross-sectional retrospective study was carried out
with the aim of assessing the prevalence, risk factors, and
genotypic characteristics of occult HBV infection in a cohort
of HIV-infected individuals living in Sicily, either na¨ıve or
treated with HAART.
2. Materials and Methods
2.1. Study Population. A cross-sectional retrospective study
was carried out on a total of 405 HBsAg-negative/HIV-
positive subjects (median age 41.0 years, 67.9%males) admit-
ted to the Infectious Diseases ward of the University Hospital
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“P. Giaccone,” Palermo, Italy, from January 2007 to December
2009, in day-hospital regimen for clinical followup of HIV
infection.
All demographic, clinical, and laboratory datawere stored
according to the Italian laws on privacy, and the research was
conducted following the Helsinki Declaration statements.
The study was reviewed and approved by the institutional
review board of the university hospital.
2.2. Laboratory Analysis. Plasma samples of HIV-infected
patients were collected and kept frozen at −80∘C until fur-
ther analysis. HBV/HCV serological markers of infec-
tion were evaluated for routinary examination by the use
of third-generation enzyme-linked-immunosorbent assays
(Vitros Immunodiagnostics, Ortho-Clinical Diagnostics,
High Wycombe, UK), and anti-HCV-positive samples were
confirmedwith a third-generation recombinant-immunoblot
assay (RIBA) (Ortho-Clinical Diagnostics, High Wycombe,
UK).
In addition, for the baseline evaluation of liver injury,
some biochemical parameters were tested: alanine/aspartate
aminotransferase (ALT/AST), total/direct/indirect biliru-
bin, gamma-glutamyl-transferase, and alkaline phosphatase
(Ortho-Clinical Diagnostics, High Wycombe, UK).
Detection of occult HBV infection was carried out in
agreementwith the key recommendations of EASL consensus
conference [16]. In this regard, up to 1mL of plasma sample
collected from HBsAg-negative patients was used during
RNA extraction, and three different in-house nested-PCR
amplification assays were applied to detect pre-S/S, pre-
Core/Core, and Pol HBV viral sequences, respectively [3].
Appropriate negative and positive controls were included in
each PCR reaction.
In our study, a “case of occult HBV infection” was defined
as a PCR-positivity in at least one of the three HBV domains
defined, after a confirmation of its specificity by sequencing
[3].
Viral nucleotide sequences obtained from each PCR-
positive sample were submitted to the web-based genotyping
program at the National Center for Biotechnology Informa-
tion (NCBI) (http://www.ncbi.nlm.nih.gov/projects/genoty-
ping/formpage.cgi) to identify the corresponding HBV gen-
otype.
All tests were performed at the Molecular Epidemiology
Laboratory of the Department of Sciences for Health Promo-
tion and Mother and Child Care “G. D’Alessandro,” Hygiene
section, University of Palermo, Italy.
2.3. Statistical Analysis. Descriptive statistics were calculated
and reported for sociodemographic and clinical characteris-
tics. Median and interquartile ranges (IQRs) were used for
description of continuous variables, while frequency analyses
for categorical variables were described with the use of
percentages.
According to data distribution, comparisons of con-
tinuous variables were conducted by using Students 𝑡-test
or Mann-Whitney 𝑈 test, while categorical variables were
compared with the Chi-square test or Fisher’s exact test, as
appropriate. A 𝑃 value < 0.05 was considered to indicate
statistical significance.
A logistic regression analysis was used to examine the
association between occult HBV status and specific sero-
logical pattern of viral infection, and the results were ex-
pressed as odds ratios (ORs) with 95% confidence intervals
(CIs).
Statistic analysis was performed by using STATA for
Apple (version 12.1MP, StataCorp, College Station, TX,USA).
3. Results
Table 1 describes the sociodemographic and serological char-
acteristics of the study population.The study group consisted
of 405HBsAg-negative/HIV-positive subjects (275males and
130 females, M : F ratio = 2.1) with a median age of 41.0 years
(IQR = 14.2 years); females were slightly younger than males
(40.3 years versus 41.7 years, resp.).
More than two-thirds of subjects (78.5%, 𝑛 = 318/405)
reported promiscuous sexual activity as risk behaviour asso-
ciated to HIV positivity, while intravenous drug use (IVDU)
was prevalent among HIV/HCV coinfected patients (44.9%,
𝑛 = 44/98).
The cohort of subjects presented in this paper mainly
consisted of native Italians (82.7%, 𝑛 = 335/405), 15.6% (𝑛 =
63/405) were Africans, and only a minority originated from
other geographic regions including Eastern Europe (1.7%, 𝑛 =
7/405).
According to the HBV/HCV serological status, five dif-
ferent categories were identified. One hundred eighty-three
HIV-positive individuals (45.2%) were negative to all of the
serologicalmarkers ofHBV infection performed in this study,
88 (21.7%) were anti-HBs + anti-HBc positive, 71 (17.5%)
showed the serological profile “anti-HBc alone,” and 63
(15.6%) were positive to anti-HBs as unique marker of infec-
tion. Overall, 24.2% of HIV-positive subjects (𝑛 = 98/405)
were coinfected with HCV; the anti-HBc alone pattern was
more frequently detected in HCV c-infected individuals than
in HCV-negative subjects (38.8% versus 10.7%; OR = 5.3,
𝑃 < 0.001).
DNA sequences of hepatitis B viruses were detected
in 24 out of 405 patients (Table 2(a)), corresponding to a
cumulative prevalence of occult HBV of 5.9% (CI
95%: 3.8–
8.7%).
HBV DNA resulted more frequently associated to the
serological pattern anti-HBc alone (11.3%, 𝑛 = 8/71),
followed by anti-HBs + anti-HBc (6.8%, 𝑛 = 6/88), and no
HBV markers (4.9%, 𝑛 = 9/183). Moreover, HBV DNA
sequences were detected in 3 out of 98 patients coinfected
with HCV (3.1%), of whom two showed the pattern anti-HBc
alone.
HIV RNA plasma levels were lower among HBV DNA-
negative than -positive individuals (1.8 log
10
HIV RNA
copies/mL versus 2.8 log
10
HIV RNA copies/mL), although
about half of OBI cases (41.7%, 𝑛 = 10/24) had undetectable
HIV viral load (≤50 HIV RNA copies/mL).
Overall, one hundred forty-five subjects (35.8%) were
na¨ıve to HAART. The most part of patients with known
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Table 1: Socio-demographic and serological characteristics of 405 HBsAg-negative/HIV-infected individuals.
Characteristic (𝑛 (%), by
column) No HBV markers Anti-HBs + Anti-HBc Anti-HBc alone Anti-HBs alone Anti-HCV
Study population (% by row) 405 183 (45.2) 88 (21.7) 71 (17.5)∗ 63 (15.6) 98 (24.2)󳵻
Sex
Male 275 (67.9) 125 (68.5) 59 (66.7) 50 (70.4) 41 (64.1) 75 (76.5)
Female 130 (32.1) 58 (31.5) 29 (33.3) 21 (29.6) 22 (35.9) 23 (23.5)
M : F ratio 2.1 2.1 2.0 2.4 1.9 3.3
Age (years, median (IQR)) 41.0 (14.2) 41.0 (12.5) 43.9 (14.4) 43.8 (11.2) 32.0 (20.2) 45.1 (5.8)
≤20 years 15 (3.7) 6 (3.3) 3 (3.4) 2 (2.8) 4 (6.3) 1 (1.0)
21–30 years 63 (15.5) 23 (12.6) 8 (9.1) 7 (9.9) 25 (39.7) 3 (3.1)
31–40 years 108 (26.7) 57 (31.1) 24 (27.3) 15 (21.1) 12 (19.0) 13 (13.3)
≥41 years 219 (54.1) 97 (53.0) 53 (60.2) 47 (66.2) 22 (34.9) 81 (82.7)
Mode of HIV transmission
Heterosexual 197 (48.6) 92 (50.3) 34 (38.6) 40 (56.3) 31 (49.2) 35 (35.7)
Homosexual 121 (29.9) 63 (34.4) 24 (27.3) 9 (12.7) 25 (39.7) 15 (15.3)
IVDU 71 (17.5) 21 (11.5) 23 (26.1) 21 (29.6) 6 (9.5) 44 (44.9)
Other/unknown 16 (4.0) 7 (3.8) 7 (8.0) 1 (1.4) 1 (1.6) 4 (4.1)
Geographic origin
Italy 335 (82.7) 160 (87.4) 67 (76.1) 51 (71.8) 57 (90.5) 91 (92.9)
Africa 63 (15.6) 20 (10.9) 17 (19.3) 20 (28.2) 6 (9.5) 7 (7.1)
Eastern Europe 4 (1.0) 2 (1.1) 2 (2.3) 0 (0) 0 (0) 0 (0)
Other 3 (0.7) 1 (0.5) 2 (2.3) 0 (0) 0 (0) 0 (0)
∗
Anti-HCV positive versus anti-HCV negative = 38.8% versus 10.7% (OR = 5.3, CI95%: 3.0–9.3, 𝑃 < 0.001).
󳵻
𝑛 = 29/405 (7.2%): HIV/HCV coinfected subjects negative to all of the serological markers of HBV infection.
IVDU: Intravenous drug use.
HAART regimens (75.1%, 𝑛 = 160/213) were taking a therapy
including lamivudine, with similar proportions between
HBV DNA-negative and -positive subjects (74.5%, 𝑛 = 149/
200 versus 84.6%, 𝑛 = 11/13). The median time of exposure
to antiretrovirals did not differ between OBI and non-OBI
patients.
Immune status was also explored comparing the two
HBV DNA groups. The CD
4
+ cell counts of HIV-infected
patients were found to be similar between groups (388
cells/mL versus 419 cells/mL, 𝑃 = 0.758), and a higher pro-
portion of subjects with CD
4
+ counts ≤ 200 cells/mL was
observed in the HBV-DNA negative group in respect to the
HBV DNA-positive group (22.9%, 𝑛 = 75/328 versus 20.0%,
𝑛 = 4/20), although the difference was not statistically sup-
ported.
Plasma concentrations of biochemical indicators of liver
damage were substantially similar in the two HBV groups
considered, either in the cohort as a whole or in HAART-
na¨ıve subjects (data not shown).
Finally, eachHIV-positive patient with occult HBV infec-
tion was genetically characterized for viral HBV genotype
classification. Almost the totality of patients with OBI were
collected during the period 2008-2009 and were infected
by genotype D viruses; only one subject, native of sub-
Saharan Africa, harboured a genotype E hepatitis B virus
(Table 2(b)).
4. Discussion
In the present study, a cohort of 405 HBsAg-negative/HIV-
infected individuals was investigated in order to assess the
impact of occult HBV infection in Sicily, and an overall
prevalence of 5.9% (CI
95%: 3.8–8.7%) was found.
In Italy, the prevalence of OBI has been previously evalu-
ated in different clinical settings [3, 9, 14, 17–19], and, to our
knowledge, this is the first work carried out in our geographic
area on a cohort of HIV-infected patients.
In this specific high-risk group, several studies have been
conducted worldwide and the available data on the frequency
of occult HBV infection are widely divergent, ranging from
0% to more than 90% [6–10], mostly depending on differ-
ences in terms of sensitivity limit of the assay used (stan-
dard/nested PCR, real-time PCR, etc.), number of HBVDNA
domains examined, biological compartment explored (liver,
plasma, or both), and composition of the study populations
[1, 20, 21].
This work confirms that occult HBV can be detected
either in patientswith serological evidence of past “apparently
resolved” HBV infection, but also in individuals with no
evident history of exposure to HBV [22].
The prevalence of OBI presented in this paper is quite
similar to that reported in European countries such as The
Netherlands [6], consistently higher than that observed in
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Table 2: Clinical, virological, and biochemical characteristics of 405 HBsAg-negative/HIV-infected individuals, according to the detection
of occult HBV infection (a) and genotypic/serological characterization of 24 OBI positive subjects (b).
(a)
Characteristic (𝑛 (%), by column) Total HBV DNA negative HBV DNA positive CI95% or 𝑃 value
Study population (𝑛 (%), by row) 405 381 (94.1) 24 (5.9) 3.8–8.7%
Serological markers of infection◻
No HBV markers 183 (45.2) 174 (95.1) 9 (4.9) 2.3–9.1%
Anti-HBs + anti-HBc 88 (21.7) 82 (93.2) 6 (6.8) 2.5–14.2%
Anti-HBc alone 71 (17.5) 63 (88.7) 8 (11.3)∗,󳵻 5.0–21.0%
Anti-HBs alone 63 (15.6) 62 (98.4) 1 (1.6) 0.1–8.5%
Anti-HCV 98 (24.2) 95 (96.9) 3 (3.1) 0.6–8.7%
HIV viral load
HIV RNA [log10 copies/mL, median (IQR)) 1.8 (3.0) 1.8 (3.0) 2.8 (3.1) 0.834
HIV RNA (≤50 copies/mL) 196 (47.9) 186 (94.9) 10 (5.1) 0.775
HAART regimen
Na¨ıve 145 (35.8) 138 (95.2) 7 (4.8)
HAART including lamivudine 160 (39.5) 149 (93.1) 11 (6.9)
HAART without lamivudine 53 (13.1) 51 (96.2) 2 (3.8)
HAART not specified 47 (11.6) 43 (91.5) 4 (8.5)
Months of treatment (median (IQR)) 55.2 (53.9) 54.9 (55.1) 58.1 (31.2) 0.954
Immunological parameters (𝑛 = 348)
CD4
+ cell counts (median (IQR)) 390 (386) 388 (382) 419 (368) 0.758
≤200 cells/mL 79 (22.7) 75 (94.9) 4 (5.1)
201–499 cells/mL 143 (41.1) 136 (95.1) 7 (4.9)
≥500 cells/mL 126 (36.2) 117 (92.9) 9 (7.1)
(b)
Case no. Sex Age (years) Geographic origin Year of sampling Risk factor Anti-HBs Anti-HBc Anti-HCV Genotype
1 F 22.3 Eastern Europe 2007 Hetero − − − D
2 F 26.8 Sub-Saharan Africa 2008 Hetero − + − D
3 F 36.2 Sub-Saharan Africa 2009 Hetero − − − D
4 M 41.0 Sub-Saharan Africa 2009 Hetero − + − E
5 M 40.0 Italy 2008 Hetero − + − D
6 M 51.8 Italy 2008 Hetero + + − D
7 F 42.6 Italy 2008 Hetero − − − D
8 F 30.3 Italy 2008 Hetero − − − D
9 M 43.9 Italy 2008 Hetero − − + D
10 M 34.4 Italy 2008 IVDU + + − D
11 F 38.0 Italy 2008 Hetero − + − D
12 M 47.8 Italy 2008 Omo − − − D
13 M 53.1 Italy 2009 IVDU + + − D
14 M 60.0 Italy 2009 Hetero − + − D
15 M 44.7 Italy 2009 Hetero + + − D
16 F 39.8 Italy 2009 Hetero + − − D
17 F 38.9 Italy 2009 Hetero − + − D
18 F 47.6 Italy 2009 Hetero − − − D
19 M 40.3 Italy 2009 Omo − − − D
20 M 43.2 Italy 2009 IVDU − + + D
21 F 39.4 Italy 2009 Hetero + + − D
22 M 35.2 Italy 2009 Omo + + − D
23 M 46.9 Italy 2009 Hetero − + + D
24 M 29.7 Italy 2009 Omo − − − D
◻
Frequency and pattern of HBV serological markers are not mutually exclusive.
∗OR = 3.7 (1.4–9.8), Mantel-Haenszel OR adjusted for anti-HCV positivity.
󳵻OR = 4.0 (1.5–10.7), Mantel-Haenszel OR adjusted for anti-HCV positivity. Analysis restricted to 145 HAART-naı¨ve patients.
CI95%; 95% confidence interval; OR: odds ratio; IQR: interquartile range; Hetero: heterosexual; Omo: homosexual; IVDU: intravenous drug use.
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Spain [13], France [21], or Taiwan [23] (0.7%, 0.6%, and 2.3%,
resp.), but lower than that reported in countries either at low
or high rates of chronic HBV [7, 20, 24].
In Sicily, the impact of OBI has been recently investigated
in different groups of subjects belonging to low- and high-
risk HBV exposure, such as general population, intravenous
drug users, patients with hepatocellular carcinoma, and
immigrants from geographic areas with high rate of HBV
infection [3, 14].
In accordance to other authors [9, 22, 25, 26], our findings
add consistency to the role of the anti-HBc alone profile as the
most adequate serological surrogate of OBI, being the only
factor significantly associated to a greater probability of OBI
detection, although higher prevalence of anti-HBc alone does
not necessarily reflect significantly higher frequency of OBI
[3, 9, 14, 22, 25, 26]. HIV infection has been proposed to have
a major effect on OBI, leading to more consistent levels in
symptomatic HIV as compared to asymptomatic HIV [27],
being significantly associatedwith lowerCD
4
+ cell counts [6].
In our experience, although HBV DNA-positive patients
showed higher levels of HIV RNA, the median CD
4
+ cell
counts were not significantly different when compared to
HBV DNA-negative group, and OBI cases were quite simi-
larly represented independently to CD
4
+ plasma levels.
Overall, the contribution of occult HBV to liver dam-
age remains unclear. Although ALT/AST flares have been
observed in HCV-positive patients in association with occult
HBV [28], in our series we did not find abnormal levels
of biochemical indicators of liver injury in OBI-positive
patients, in accordance to the overall trend in the literature
[9, 18, 29], also in correlation to the immunosuppressed state
of HIV-positive subjects [12, 30].
In general, HCV coinfection has been considered as one
of the main reasons for inducing OBI [31], and prevalences of
occult HBV infection have been reported to be significantly
higher in HCV chronically coinfected patients as compared
to HCV-negative individuals [32, 33].
In Italy, the impact of OBI in cohorts of HIV-positive
patients coinfected with hepatitis C virus was recently inves-
tigated, either in plasma samples or liver biopsies [9, 18],
reporting consistent prevalences of OBI and suggesting a
strong correlation with HCV. Nevertheless, in accordance
with other recently published studies [34, 35], in our cohort
occult HBV infection was uncommon among anti-HCV
positive subjects, and the high frequency of HAART-treated
individualswithin this specific group (most of themassuming
a lamivudine-based therapy) could partially explain the low
prevalence found [36, 37].
The positive association between HIV and chronic hep-
atitis B infection is well known, in terms of higher levels
of HBV DNA and detection of HBV antigens [38, 39],
especially before the availability of HAART. More recently,
the widespread introduction of HAART in clinical practice,
commonly associated withHIV/HBVdually active drugs (i.e.
lamivudine, tenofovir, and emtricitabine), plays an important
role in the suppression of virus replication [17], leading to
lower levels of OBI in HAART-treated HIV-positive subjects.
However, as similarly reported by other authors in Italy
[9, 40], in our study population occult HBV infections
were found either in HAART na¨ıve or treated patients, and
lamivudine-based HAART did not exert an important effect
on HBV DNA detectability.
Finally, in this study, the most part of occult infections
were sustained by genotype D HBV viral strains, which is
consistent with the genotypes circulating in Sicily [14]. In
this regard, although it has been suggested that in occult
HBV infection preferentially occurring genotype D viruses
[9, 35, 41–43], HBV genotypes other than D, including the C
genotype [44, 45] as well as A, G, and E genotypes [14, 22, 46],
have been detected in OBI.
Our findings should be interpreted in light of the possible
limitations of this study, including the cross-sectional retro-
spective design, the use of a single time point testing without
any followup, and the biological compartment explored to
detect HBV-DNA. Moreover, the limited sample size may
have reduced our ability to detect differences between groups,
and the results, as such, may not be generalizable to other
settings.
Nevertheless, despite these limitations, our results add
evidence to the knowledge in this field, in a geographic area
where the increasing trend in migration flows could play an
important role in promoting a modification of the local HBV
epidemiology.
5. Conclusions
The surveillance of occult HBV infection and its genetic
variability is recommended to better evaluate the viral
dynamics and their role in the outcome of the liver damage
in HIV/HCV coinfected as well as in healthy individuals with
HBV serological pattern suggestive of latent HBV infection.
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